Article Sidebar

Submitted
22 December 2023
Accepted
1 April 2024
Published
10 March 2024
Download
PDF
Statistic
Read Counter : 178 Download : 168

Main Article Content

Abstract

Highlights:
1. This study, conducted at a tertiary hospital, was the first to analyze the correlation between thyroid status and clinical activity score in thyroid eye disease.
2. This study offers valuable information regarding the crucial role of thyroid stimulating hormone (TSH) in determining the clinical activity score of thyroid eye disease.


 


Abstract


Thyroid eye disease is an autoimmune disorder characterized by inflammation of the orbital and periorbital tissues. This condition can lead to vision impairment, which is a notable manifestation of thyroid disease. The symptoms of thyroid disease reflected the level of inflammatory activity, whereas the clinical activity score was indicative of active and inactive phases. This retrospective analysis explored the intricate association between thyroid status and clinical activity score in thyroid eye disease patients, with the hope of providing a foundation for further research on the association between thyroid status and the occurrence of TED. This study utilized medical records from the years 2019 to 2022 from the Outpatient Department of Ophthalmic Oncology of Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. The variables examined in this study were thyroid status and the clinical activity score of thyroid eye disease. The statistical analysis was performed using Phi and Cramer's V as well as Spearman's correlation test (p<0.05). A total of 88 patients were diagnosed with thyroid eye disease during the study period. Thyroid eye disease primarily affected female patients (58%) and those who had a mean age of ≥41 years (58%). The Phi and Cramer's V analyses indicated no significant association (p > 0.05) between thyroid status and clinical activity score in thyroid eye disease patients. Intriguingly, the results exhibited the presence of euthyroidism as well as both overt and subclinical hypothyroidism and hyperthyroidism, regardless of the clinical activity score. Additionally, the Spearman test that incorporated the levels of thyroid hormones, i.e., triiodothyronine (T3), thyroxine (T4), thyroid stimulating hormone (TSH), and free thyroxine (FT4), showed a significant negative correlation (p<0.05) between TSH and clinical activity score. In conclusion, THS plays a crucial role in determining the clinical activity score of thyroid eye disease patients. This study underscores the imperative for further research to comprehensively elucidate the intricate correlation between TSH and clinical activity score.

Keywords

Thyroid eye disease clinical activity score thyroid hormone thyroid stimulating hormone (TSH) human and health

Article Details

License

Copyright (c) 2024 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

Author Biography

Soebagijo Adi Soelistijo, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

Department : Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

Rank : IV/E

How to Cite
Hasna Shahida Amatlulloh, Delfitri Lutfi, Soebagijo Adi Soelistijo, Reni Prastyani, & Muhammad Valeri Alhakiim. (2024). Significant Role of Thyroid Stimulating Hormone in the Clinical Activity Score of Thyroid Eye Disease at a Tertiary Hospital in Surabaya, Indonesia. Folia Medica Indonesiana, 60(1), 33–39. https://doi.org/10.20473/fmi.v60i1.52948
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, et al (2015). Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. Journal of Ophthalmology 2015. doi: 10.1155/2015/249125
  2. Bartalena L, Kahaly GJ, Baldeschi L, et al (2021). The 2021 european group on graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves' orbitopathy. European Journal of Endocrinology 185, 43–67. doi: 10.1530/EJE-21-0479.
  3. Calsolaro V, Niccolai F, Pasqualetti G, et al (2019). Overt and subclinical hypothyroidism in the elderly: When to treat?. Frontiers in Endocrinology. doi: 10.3389/fendo.2019.00177.
  4. Castello R, Caputo M (2019). Thyroid diseases and gender. Journal of Sex- and Gender-Specific Medicine 5, 136–141. doi: 10.1723/3245.32148.
  5. Cockerham KP, Padnick-Silver L, Stuertz N, et al (2021). Quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmology and Therapy 10, 975–987. doi: 10.1007/s40123-021-00385-8.
  6. Douglas RS, Kahaly GJ, Patel A, et al (2020). Teprotumumab for the treatment of active thyroid eye disease. New England Journal of Medicine 382, 341–352. doi: 10.1056/NEJMoa1910434.
  7. Eshraghi B, Pourazizi M, Abbasi M, et al (2023). Hypo vs. hyperthyroid eye disease: is there any difference? BMC Ophthalmology 23, 58. doi: 10.1186/s12886-023-02806-7.
  8. Fatmariyanti S, Lutfi D, Sidohutomo A (2022). Waspada mata menonjol. Mimbar 26, 14–15. Available at: https://rsudrsoetomo.jatimprov.go.id /storage/files/pkrs/mimbar/mimbarVol26no2.pdf
  9. Gandhi R, Durairaj VD, Shah K (2024). Thyroid eye disease. MediaWiki. Available at: https://eyewiki. aao.org/Thyroid_Eye_Disease#Diagnostic_procedures.
  10. Ganesan K, Anastasopoulou C, Wadud K (2024). Euthyroid sick syndrome. Available at: http://www.ncbi.nlm.nih.gov/pubmed/30325734.
  11. Geetha K, Baboo SS (2016). An empirical model for thyroid disease classification using evolutionary multivariate bayseian prediction method. Global Journal of Computer Science and Technology 16, 1–9. Available at: https://computerresearch.org/ index.php/computer/article/view/1353.
  12. IBM Corp (2019). IBM SPSS Statistics for Macintosh, Version 26.0. Armonk, NY: IBM Corp. Avaliable at: https://www.ibm.com/id-id/products/spss-statistics.
  13. Iñiguez-Ariza NM, Sharma A, Garrity JA, et al (2021). The "quiet TED””a special subgroup of thyroid eye disease. Ophthalmic Plastic & Reconstructive Surgery 37, 551–555. doi: 10.1097/IOP.0000000000001942/
  14. Kannan L, Shaw PA, Morley MP, et al (2018). Thyroid dysfunction in heart failure and cardiovascular outcomes. Circulation: Heart Failure doi: 10.1161/CIRCHEARTFAILURE.118 .005266.
  15. Levy N, Leiba H, Landau K, et al (2022). Clinical profile of 80-year-old and older thyroid eye disease patients. Graefe's Archive for Clinical and Experimental Ophthalmology. doi: 10.1007/s0041 7-022-05627-4.
  16. Mathew P, Kaur J, Rawla P (2024). Hyper-thyroidism. Available at: http://www.ncbi.n lm.nih.gov/pubmed/27521067.
  17. McAlinden C (2014). An overview of thyroid eye disease. Eye and Vision 1, 9. doi: 10.1186/s40662-014-0009-8.
  18. Meng Z, Liu M, Zhang Q, et al (2015). Gender and age impact on the association between thyroid-stimulating hormone and serum lipids. Medicine (Baltimore) 94, e2186. doi: 10.1097/MD.0000000 000002186.
  19. Muñoz-Ortiz J, Sierra-Cote MC, Zapata-Bravo E, et al (2020). Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature. Systematic Reviews 9, 201. doi: 10.1186/s13643-020-01459-7.
  20. Muralidhar A, Das S, Tiple S (2020). Clinical profile of thyroid eye disease and factors predictive of disease severity. Indian Journal of Ophthalmology 68, 1629. doi: 10.4103/ijo.IJO_104_20.
  21. Nagai H, Amemiya T, Suzuki H (2023). Risk factors for amiodarone-induced liver injury: A retrospective analysis of medical records. Int. Journal of Clinical Pharmacology and Therapeutics 61, 455–459. doi: 10.5414/CP2044 28.
  22. Rashad R, Pinto R, Li E, Sohrab, et al (2022). Thyroid eye disease. Life 12, 1-17. doi: 10.3390/LIFE12122084
  23. Rhee CM, Ravel VA, Streja E, et al (2016). Thyroid functional disease and mortality in a national peritoneal dialysis cohort. The Journal of Clinical Endocrinology & Metabolism 101, 4054–4061. doi: 10.1210/jc.2016-1691.
  24. Şahlı E, Gündüz K (2017). Thyroid-associated ophthalmopathy. Turkish Journal of Ophthal mology 47, 94. doi: 10.4274/TJO.80688
  25. Salvi M, Campi I (2015). Medical treatment of graves' orbitopathy. Hormone and Metabolic Research 47, 779–788. doi: 10.1055/s-0035-1554721.
  26. Savitri AD, Sutjahjo A, Soelistijo SA, et al (2019). Comparison of thyroid stimulating hormone receptor antibody (Trab) in graves' disease patients with and without ophtalmopathy. New Armenian Medical Journal 13, 39–46. Available at: https://scholar.unair.ac.id/en/publications/com parison-of-thyroid-stimulating-hormone-receptor-antibody-trab-.
  27. Schattner A, Voichanski S, Pollack R, et al (2023). Euthyroid graves' ophthalmopathy. Q QJM: An International Journal of Medicine 116, 942–943. doi: 10.1093/qjmed/hcad176.
  28. Shahid MA, Ashraf MA, Sharma S (2024). Physiology, thyroid hormone. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29652955.
  29. Wang Y, Padnick-Silver L, Francis-Sedlak M, et al (2022). Inflammatory and noninflammatory thyroid eye disease: Comparison of disease signs, symptoms, and quality of life in patients in the United States. Endocrine Practice 28, 842–846. doi: 10.1016/j.eprac.2022.06.003.
  30. Yu CY, Ford, RL, Wester ST, et al (2022). Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. Indian Journal of Ophthalmology 70, 2335. doi: 10.4103/IJO.IJO_3217_21